临床与实验病理学杂志2019，Vol.35Issue(1)：6-10,5.DOI:10.13315/j.cnki.cjcep.2019.01.002
胃腺癌中c-MET、EGFR和HER-2的表达及其与临床病理特征的分析
Expression of c-MET, EGFR and HER-2 of human gastric adenocarcinoma
摘要
Abstract
Purpose To investigate the expression status and their clinical significances of c-MET, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER-2) in gastric adenocarcinoma (GC). Methods Tissue samples from 442 cases of GC in patients who accepted D2/D3 radical gastrectomy with R0 resection were stained by immunohistochemistry against c-MET, EGFR and HER-2.Results Over expression of c-MET, EGFR and HER-2 was identified in 195/442 (44.1％), 47/442 (10.6％) and 152/442 (34.4％) GC patients, respectively. Over expression of cMET was more often identified in GC patients with deeper T (P= 0.016), nerve involvement (P = 0.006) and the Lauren diffuse type (P = 0.029). EGFR in cases with vessel permeation (P = 0.012), and HER-2 in cases of distant metastasis (P =0.031), non-nerve involvement (P = 0.024), the Lauren intestinal type (P < 0.001) and G1/G2 grade (P < 0.001). Conclusion The receptors tyrosine kinase (RTKs) markers of cMET, EGFR and HER-2 might involve in the advance of GC, such as invasion and metastasis. The expression status of them could be used as the risk prediction and even the basis for future personalized therapy, especially for tyrosine kinase inhibitor (TKI) therapy, for GC patients.关键词
胃肿瘤/腺癌/c-MET/EGFR/HER-2/免疫组织化学Key words
stomach neoplasm/adenocarcinoma/c-MET/EGFR/HER-2/immunohistochemistry分类
医药卫生引用本文复制引用
李琳,付尧,吴鸿雁,陈骏,陈洁宇,孙琦,徐新运,王益华,樊祥山..胃腺癌中c-MET、EGFR和HER-2的表达及其与临床病理特征的分析[J].临床与实验病理学杂志,2019,35(1):6-10,5.基金项目
国家自然科学基金(81101815) （81101815）
